Marina Remennik

Cooley advised Rani Therapeutics on its $73.3 million initial public offering of 6,666,667 shares of Class A common stock. Rani Therapeutics, whose securities now trade on the Nasdaq Global Market under the symbol RANI, is a clinical-stage biotherapeutics company focused on advancing technologies to enable the development of orally administered biologics. Partners Josh Seidenfeld, Mark Weeks, John McKenna and Charlie Kim led the Cooley team.

Cooley advised Dynavax Technologies on its offering of $200 million principal amount of 2.50% convertible senior notes due 2026. Dynavax Technologies, whose securities trade on the Nasdaq Capital Market under the symbol DVAX, is a biopharmaceutical company focused on developing and commercializing novel vaccines. Partners Steve Przesmicki, Mischi a Marca and Jason Savich le the Cooley team.

Cooley advised TiVo on its agreement to combine with Xperi Corporation in an all-stock transaction, representing approximately $3 billion of combined enterprise value. Expected to close in Q2 2020, the merger creates a leading consumer and entertainment technology business and one of the industry’s largest intellectual property licensing platforms. Jon Gavenman, Steve Tonsfeldt and Ian Nussbaum led the Cooley team advising TiVo.

Cooley advised Sonim Technologies on its $39.3 million initial public offering of 3,571,429 shares of common stock. Jon Gavenman and Mike Tenta led the Cooley team advising Sonim Technologies.

Oppenheimer acted as lead book-running manager and Lake Street Capital Markets acted as joint book-running manager for the offering. National Securities Corporation acted as co-manager for the offering.

Sonim is a leading U.S. provider of ultra-rugged mobility solutions designed specifically for task workers physically engaged in their work environments. The company’s shares now trade on the Nasdaq Global Market under the symbol “SONM.”

On July 8, 2016, the Antitrust Division of the US Department of Justice and the Federal Trade Commission granted early termination of the waiting period under the Hart-Scott-Rodino Act, or HSR, for Rovi's proposed $1.1 billion acquisition of TiVo. Early termination is granted if the FTC and DOJ have completed their regulatory review and determine that no enforcement action is necessary. The proposed acquisition, which was announced on April 29, 2016, is subject to additional customary closing conditions and is expected to close in Q3 of 2016.

The Deal reported on June 16 that Rovi refiled for clearance under HSR to give antitrust officials another month to decide whether to launch an extended investigation of the merger or to let it close without further scrutiny.

Rovi creates personalized and data-driven ways for viewers to discover the right entertainment and for providers to discover the right audiences, leading innovation in content discovery since introduction of the first on-screen program guide in 1981. TiVo, the inventor of the DVR, offers innovative cloud-based Software-as-a-Service solutions that enable viewers to consume content across multiple screens in and out of the home. The combined company will have worldwide portfolios of 6,000+ patents and pending applications.

Cooley is advising Rovi on both the acquisition and the antitrust aspects of the transaction.